tiprankstipranks

Transcenta Unveils Promising Osemitamab Trial Results at ASCO 2025

Story Highlights
Transcenta Unveils Promising Osemitamab Trial Results at ASCO 2025

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Transcenta Holding Limited ( (HK:6628) ) is now available.

Transcenta Holding Limited announced promising new data from its Phase II trial of Osemitamab (TST001) for advanced gastric or gastroesophageal junction cancer, presented at the 2025 ASCO Annual Meeting. The trial results indicate significant survival benefits, with a median overall survival of 20.4 months for all patients and 21.7 months for those with higher CLDN18.2 expression. These findings strengthen the company’s commitment to advancing this treatment, potentially improving patient outcomes and enhancing its position in the oncology market.

More about Transcenta Holding Limited

Transcenta Holding Limited operates in the biotechnology industry, focusing on the development of innovative antibody-based therapeutics. The company is particularly involved in creating treatments targeting cancer, with a market focus on gastric or gastroesophageal junction (G/GEJ) and pancreatic cancers.

Average Trading Volume: 1,218,151

Technical Sentiment Signal: Hold

Current Market Cap: HK$692.1M

For an in-depth examination of 6628 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1